Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Renflexis

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

NHS says Humira biosimilar deal will save £300m

AbbVie also submitted a bid into tender process

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

- PMLiVE

First Humira biosimilars reach EU market

World's biggest selling medicine to lose billions in sales

- PMLiVE

Daily Brief: European approvals for BMS’ Opdivo, Aegerion’s lipodystrophy treatment, Pfizer’s biosimilar and Xeljanz

Will Pfizer spark price war with its Herceptin biosimilar?

- PMLiVE

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab’s OX40 candidate

The latest from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links